Teva Pharmaceutical Industries (TEVA) Long-Term Debt Issuances (2017 - 2025)

Teva Pharmaceutical Industries (TEVA) recorded quarterly Long-Term Debt Issuances of $2.3 billion in Q2 2025, down 5.96% on a QoQ basis from $2.5 billion in Q1 2023.

Teva Pharmaceutical Industries (TEVA) Long-Term Debt Issuances (2017 - 2025) Analysis & Trends

Teva Pharmaceutical Industries has disclosed Long-Term Debt Issuances across 4 years of filings, most recently posting $2.3 billion for Q2 2025.

  • Quarterly Long-Term Debt Issuances changed N/A year-over-year to $2.3 billion in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $2.3 billion (changed N/A YoY) and the FY2025 annual result came in at $2.3 billion, changed N/A from the prior year.
  • Long-Term Debt Issuances declined to $2.3 billion in Q2 2025, from $2.5 billion in the prior quarter.
  • Over five years, Long-Term Debt Issuances peaked at $2.5 billion in Q1 2023 and troughed at $2.3 billion in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Teva Pharmaceutical Industries 39.97 Bn 36.23 Bn 1.97 Bn -
2 Zoetis 33.59 Bn 31.65 Bn 1.62 Bn -
3 United Therapeutics 23.75 Bn 21.60 Bn 648.10 Mn -
4 Neurocrine Biosciences 16.10 Bn 14.78 Bn 800.70 Mn -
5 Aurora Cannabis 15.56 Bn 15.47 Bn 21.72 Mn -
6 Elanco Animal Health 12.04 Bn 11.61 Bn 785.00 Mn -
7 Alkermes 7.36 Bn 6.84 Bn -116.06 Mn 1.51 Bn
8 Lantheus Holdings 6.74 Bn 6.24 Bn 230.92 Mn -
9 Liquidia 6.27 Bn 6.04 Bn 121.79 Mn -
10 Hims & Hers Health 6.15 Bn 5.40 Bn 396.79 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2025 2.31 Bn
Jun 30, 2025 2.31 Bn
Mar 31, 2023 2.45 Bn
Mar 31, 2023 2.45 Bn
Sep 30, 2018 -1.00 Mn
Sep 30, 2018 -1.00 Mn
Jun 30, 2018 -5.00 Mn
Jun 30, 2018 -5.00 Mn
Mar 31, 2018 4.44 Bn
Mar 31, 2018 4.44 Bn
Dec 31, 2017 -1.00 Mn
Dec 31, 2017 -1.00 Mn
Sep 30, 2017 -14.00 Mn
Sep 30, 2017 -14.00 Mn